A 70-year-old woman from Kota, Rajasthan, experienced a significant shift in her advanced lung cancer treatment after doctors opted for genomic testing. The test identified a clinically important genetic alteration known as a MET exon 14 skipping mutation. This mutation, often referred to as a 'driver mutation,' is associated with tumor growth and disease progression. Cancers driven by this mutation can be particularly challenging to manage, as they may not respond well to conventional treatments alone. By identifying this mutation, the oncologist gained a deeper understanding of the tumor's behavior, explained its progression, and tailored a more personalized treatment approach using therapies that specifically target the altered MET pathway.
Initial Diagnosis and Treatment
The woman initially visited a doctor after experiencing persistent coughing accompanied by blood. Medical reports confirmed Stage III lung cancer, and treatment was started immediately. However, despite receiving initial chemotherapy, the disease progressed to Stage IV.
Second Opinion and Genomic Profiling
When the disease advanced, the family sought a second opinion. The consulting oncologist decided to examine the cancer more closely, looking for molecular alterations influencing the disease's course. The patient's sample was sent for comprehensive genomic profiling of tumor cells. The report revealed the MET exon 14 skipping mutation, a genetic alteration known to occur in a subset of lung cancer patients. This mutation is actionable, meaning a targeted treatment option is available.
Targeted Approach and Recovery
This finding enabled the oncologist to adopt a targeted approach, resulting in a positive response and subsequent recovery. Over time, the woman was able to fight the disease and return to her normal daily activities.
Expert Insights
Dr. Bharat Bhosale, Medical Oncologist and Founder of BB Precision Oncocare Centre, stated, “Every cancer behaves differently, and understanding the molecular characteristics of a tumor can complement clinical assessment and guide treatment decisions. In this patient's case, identifying the MET exon 14 skipping mutation offered important insights that informed treatment decisions. Such genomic findings are increasingly enabling a more personalized approach to cancer care.”
Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Many patients are diagnosed only after the disease has reached an advanced stage. While conventional diagnostic methods remain important, genetic testing is increasingly used to identify specific genetic alterations that guide treatment planning and disease management for better outcomes.
Dr. Prashanth Bagali, Head of Scientific Affairs – Oncology at MedGenome Labs Ltd, added, “Cancer care is becoming increasingly personalized, and genomics plays an important role in helping clinicians understand the unique biology of an individual's cancer and make more informed treatment decisions. As awareness and access to genomic testing grow, molecular insights are becoming an increasingly important component of personalized cancer care.”
Experts note that advances in genomic testing help doctors identify actionable mutations that may not be detected through routine diagnostic evaluation alone. These insights support more tailored treatment strategies across different cancer types, enabling more accurate and accessible care.
